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Abstract 
The purpose of this research was to determine the level of adherence among HIV infected 
pregnant women on prevention of mother to child transmission (PMTCT) antiretroviral 
therapy, and to establish the factors that contribute to poor adherence and their relative 
importance, in order to suggest intervention strategies that will improve treatment adherence 
among this population. 
The study was conducted in Area W Clinic, Francistown Botswana, and was a prospective 
cross sectional study using semi-structured questionnaire, and data collection form. In total, 
61 pregnant women participated in the study and were all within three to nine months 
gestation, and had been enrolled into the PMTCT program at least more than one month 
previously. The following were their characteristics: 75% were within the ages of 26 to 42 
years old, 90% were single, 81% had attained secondary school education, and 60% were 
unemployed. Adherence was considered optimum if greater than or equal to 95%.  
The participants demonstrated a good knowledge of the importance of PMTCT treatment 
adherence. Reported optimum adherence levels were 84% by virtual analogue assessment, 
and 82% by pill count. Ninety eight percent of participants reported they did not miss any 
dose during the last three days before the interview. The most important factors influencing 
adherence from the study were pregnancy related illnesses, medication side effects, and 
month of pregnancy of the patient as participants tended to adhere less as they got closer to 
delivery. It is therefore important for care-givers to carefully monitor patients for these 
effects, and to carry out continuous adherence counselling with special attention given to 
those approaching delivery in order to improve or maintain overall adherence to PMTCT 
therapy. 
 
In conclusion, adherence levels to PMTCT therapy among the population sampled was high 
but can be further enhanced with interventions designed to cover and improve the highlighted 
areas in the implementation of the preventive therapy. 
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Opsomming 
 
Altesaam 61 swanger vroue het deelgeneem aan hierdie studie, wat daarop uit was om 
getrouheid in antiretrovirale behandeling vir die voorkoming van moeder-na-kind-oordrag 
(PMTCT) van MIV te bepaal, vas te stel watter faktore tot swak behandelingsgetrouheid 
bydra sowel as watter relatiewe gewig aan elke faktor geheg kan word. Die einddoel was om 
intervensiestrategieë aan te beveel wat behandelingsgetrouheid onder die populasie van die 
kliniek in area W, Francistown, Botswana, sal verbeter. 
 
Dit blyk dat die deelnemers die belang van behandelingsgetrouheid verstaan: ’n Totaal van 
84% het optimale getrouheidsvlakke van >95% deur middel van virtuele analoogassessering 
aangemeld, en 82% deur middel van ’n piltelling. Daarbenewens het 98% bevestig dat hulle 
in die drie dae voor die onderhoud geen medisynedosisse oorgeslaan het nie. Die 
beduidendste faktore wat behandelingsgetrouheid beïnvloed, is swangerskapsverwante siekte, 
newe-effekte van die medisyne sowel as die maand van swangerskap, aangesien getrouheid 
oënskynlik afneem namate die swangerskap vorder. Dus is dit belangrik om pasiënte deeglik 
hiervoor dop te hou en voortdurend berading met betrekking tot behandelingsgetrouheid te 
voorsien, met ’n bepaalde klem op diegene wie se bevalling nader kom, ten einde algehele 
PMTCT-behandelingsgetrouheid te verbeter of te handhaaf. 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
4 
 
 
Acknowledgment 
 
With special thanks and appreciation, I wish to acknowledge my supervisor, Dr. Greg Munro 
for his help, guidance, and mentoring which made it possible for this research to become a 
success.  
 
I wish to thank Ms. Keletso Othusitse for all her efforts and assistance in the data collection 
process. I also wish to thank Mr. Chidozie Njoku for his impute on the data analysis. My 
appreciation also goes to the Greater Francistown District health Management Team, the 
Health Research and Development Division of the Ministry of Health, and the Research and 
Ethics Committee of Stellenbosch University for giving their approval for the conduct of this 
research. 
 
My sincere appreciation also goes to the staff of the Department of HIV and AIDS 
Prevention and Care, Botswana Ministry of Health for granting me access to the PMTCT 
records of the department. I also wish to acknowledge and thank the Botswana-Harvard 
AIDS Institute Partnership for HIV and AIDS Research and Education for granting me access 
to their research library. 
 
My special thanks and gratitude also go to all the respondents who participated in the study, 
and to the local staff of the Area W Clinic for their kind co-operation and support. 
 
Finally, my deepest appreciation goes to my dear wife Mrs. Mary Ochigbo, and our lovely 
children Elsie Ochigbo and Roy Ochigbo for being a pillar of support and encouragement to 
me, and for their patience and understanding all through the entire duration of the course.  
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
5 
 
Dedication 
 
This work is dedicated to Elsie and Roy, my Jesus babies. 
To God is the glory. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
6 
 
Abbreviations used 
 
AIDS- Acquired Immune Deficiency Syndrome 
ALV- Aluvia (Lopinavir 200mg boosted by Ritonavir 50mg tablets) 
ANC- Antenatal Clinic 
ART- Antiretroviral Therapy 
ARV- Antiretroviral 
ATRIPLA- Tenofovir 300mg, Emtricibine 200mg, and Efavirenz 600mg tablets 
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1. BACKGROUND 
 
The World Health Organization (WHO) describes Mother-to-child transmission (MTCT) of 
HIV as the transmission of the HIV virus from a HIV positive mother to her child during 
pregnancy, labour, delivery, or breastfeeding leading to established HIV infection in the child 
(WHO 2010). Prophylactic antiretroviral therapy for the prevention of HIV infection from a 
pregnant mother to her child is known as prevention-of-mother-to-child-transmission 
(PMTCT). It involves medication with antiretroviral agents for the mother during pregnancy 
and eventually for the new born to prevent viral transmission or infection of the child. 
Transmission rates of HIV from mother to child in the absence of prophylactic intervention 
ranges from 20-45 %, and can be reduced to below 5% when effective PMTCT interventions 
are employed (WHO 2010). In Sub-Saharan Africa in 2008, an estimated 45% of pregnant 
women who were HIV positive accessed antiretroviral medication for PMTCT (WHO 2009). 
 
Botswana has a very comprehensive and free antiretroviral roll out program for her citizens. 
The program is locally known as MASA, a Setswana word meaning “A new dawn”, of which 
the PMTCT is a part of. The PMTCT program was introduced in 1999 and it is presently 
widely available in health facilities nationwide (National AIDS Coordinating Agency NACA, 
2008). Botswana is one of the Sub-Sahara African countries reported to have achieved the 
2001 United Nations General Assembly Special Session (UNGASS) global target of an 80% 
PMTCT coverage of antiretroviral therapy for HIV positive pregnant women and their 
children by the year 2010 (WHO 2010).  
 
According to the UNICEF 2010 Botswana PMTCT Factsheet, as at 2010 an estimated 16,000 
children between the ages of birth to fourteen years are living with HIV and AIDS, and an 
estimated 13,000 pregnant women are living with HIV and AIDS. A total of 73.3% of 
pregnant women in Botswana attend at least four ante-natal clinic visits during pregnancy, 
and with all ante-natal facilities in the country presently providing HIV testing and 
antiretroviral medication for PMTCT, the prevention of mother to child infection continues to 
improve (UNICEF 2010). The United States Agency for International Development (USAID 
2010) reported that Botswana is one of only four countries in the world that provides more 
than 75% antiretroviral medication coverage for PMTCT. Their records also show that by the 
end of 2007, there was a recorded fivefold decline of HIV infection among neonates born to 
HIV infected mothers from 1999 to 2007 (USAID 2010). 
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 For any antiretroviral roll out initiative to be successful, those affected must adhere to the 
treatment regimen with adherence levels above 95%. Pregnant mothers undergoing PMTCT 
may have issues of poor adherence to treatment even after pre-treatment initiation 
counselling, the causes of which the study aimed to identify. The peculiar nature and 
circumstances surrounding pregnant women who are HIV positive and have to undergo 
PMTCT to save their unborn children from HIV infection may have an impact on their ability 
to achieve desired levels of treatment adherence. It was therefore the intention of the research 
to uncover, and bring focus to the factors responsible for non-adherence to PMTCT therapy 
despite adequate adherence counselling, and the influence of identified adherence barriers on 
attaining recommended levels of treatment adherence, with a view of recommending 
appropriate intervention measures that can improve overall adherence to antiretroviral 
PMTCT treatment. 
 
The research was conducted in Area W Clinic in Francistown, Botswana. Francistown is the 
second largest city in Botswana, located in the North-eastern part of the country. The Area W 
Clinic is one of the popular Government owned clinics in the city, providing among other 
services, antiretroviral treatment roll out services for the public. It is under the management 
of the Greater Francistown District Health Management Team, in affiliation with the 
Botswana Ministry of Health. The clinic also provides antiretroviral therapy for the PMTCT 
program in Francistown for pregnant women along with ante-natal clinic (ANC) services. It 
has good information management practices, and keeps an up to date pill count record of 
antiretroviral drugs dispensed to patients including pregnant women on PMTCT. These were 
the reasons why the clinic was chosen for this study, along with the fact that the investigator 
resides in the area. 
 
2. RESEARCH QUESTION 
 
The PMTCT program in Botswana currently enjoys good success rates but with room for 
improvement. Sustenance or improvement can only be achieved with proper and adequate 
adherence to the preventive therapy. There is therefore need to assess the level of adherence 
and the factors that impede it, in order to design and implement appropriate interventions that 
will improve the overall adherence to PMTCT. 
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The following therefore were the questions this research intended to answer.  What is the 
level of adherence to PMTCT antiretroviral therapy among pregnant women in Area W 
Clinic in Francistown Botswana? What are the factors responsible for poor adherence to 
antiretroviral treatment in an informed pregnant mother undergoing PMTCT who, through 
counselling, is aware of the importance of adherence and the dangers of treatment failure that 
may result from non-optimum adherence? What are the factors that influence adherence to 
PMTCT therapy and what is their relative importance? 
  
3. SIGNIFICANCE OF RESEARCH 
 
Most of the studies conducted on antiretroviral treatment adherence focuses on regular 
patients with few concentrating on pregnant women and their adherence particularly to 
PMTCT. This research aims to unearth more information on the level of adherence to 
PMTCT therapy and the factors that are causing poor adherence in this population despite 
pre-treatment initiation counselling. 
 
Botswana has a highly successful PMTCT program in place. However, over the past decade 
of program implementation, the infant HIV transmission rate has not fallen to below 2% as 
portrayed possible by the WHO (2007). The reason for this may be related to medication 
adherence. It is therefore important to determine the level of adherence to PMTCT 
antiretroviral therapy, and to establish the factors that contribute to poor adherence in order to 
develop adherence intervention strategies that can further improve the impact of the PMTCT 
program.  
 
4. LITERATURE REVIEW 
 
4.1 HIV and PMTCT in Botswana 
 
HIV and AIDS is a leading public health challenge in Botswana since the diagnosis of the 
first AIDS case in 1985 (Botswana Ministry of Health MOH, 2012). It has since become an 
epidemic with a recorded prevalence of 32.5% in 2009 (Botswana Central Statistics Office, 
2009). The prevalence rate of HIV in Botswana is higher in women than in men, with 
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national prevalence rates among pregnant women aged between 15 and 49 years reported at 
31.8%. In 2001, the HIV prevalence among pregnant women accessing ante-natal clinic 
services in Botswana was 36.2% (Ministry of Health MOH Botswana National Guidelines 
PMTCT 2011). 
 
A mode of transmission of HIV infection is the vertical transmission which is transmission 
from a pregnant mother to an unborn child. During pregnancy or delivery, an infected 
pregnant mother may transmit the HIV virus to her baby. Transmission can also occur during 
breastfeeding in the absence of appropriate prophylactic interventions. 
According to the WHO (2007), MTCT alone accounts for over 10% of all HIV infections 
globally, and over 90% of new infections presenting in infants occur through MTCT.  
Presently, the treatment of a pregnant mother with antiretroviral medication and the treatment 
of the newborn postpartum (after delivery) can prevent transmission of the virus to the 
newborn baby. The comprehensive use of antiretroviral drugs to prevent this mode of 
transmission is known as PMTCT therapy. 
 
The United Nations Millennium Development Goals (MDG) to be met by 2015 consist 
among others the reduction, by two thirds, of the mortality rate among children under five 
years old, reduction of maternal mortality ratio by three quarters, and to halt and begin to 
reverse the spread of HIV and AIDS. The global success or failure of PMTCT efforts directly 
affects the achievement of these three millennium development goals (WHO 2007). The 
United Nations therefore developed a comprehensive approach consisting of a four-pronged 
strategy for PMTCT to “address a broad range of HIV-related prevention, care, and treatment 
and support needs of pregnant women, mothers, their children and families” (WHO 2007).  
 
The WHO four-pronged PMTCT strategy are- 
i. Primary prevention of HIV infection among women, especially young women. 
ii. Prevention of unintended pregnancies among HIV-infected women. 
iii. Provision of specific interventions to reduce HIV transmission from HIV-infected 
women to their infants. 
iv. Provision of treatment, care and support for HIV-infected mothers, their infants and 
family. 
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The Botswana PMTCT approach was designed in accordance with WHO guidelines and 
includes the four elements of the comprehensive approach (MOH Botswana National 
Guidelines PMTCT 2011). The PMTCT program in Botswana started in 1999, and by July of 
2000 the country embarked on a national roll-out of the program under the Sexual and 
Reproductive Health (SRH) services. By November 2001, all public healthcare facilities in 
the country were offering PMTCT services. With the advent of the National ARV Program in 
2002 expanding antiretroviral treatment access, the PMTCT program became more 
widespread with increased program uptake and improved services. Availability of routine 
HIV testing, post-test counselling, eligibility analysis and provision of triple prophylaxis or 
HAART initiation, adoption of safe obstetric practices, infant HIV testing and infant feeding 
under the auspices of the PMTCT program all contribute to making the Botswana PMTCT 
program a success story (MOH Botswana National Guidelines PMTCT 2011). 
 
The program uptake has grown from 27% in 2002 to 93% in 2011. The number of women 
tested during ante-natal clinic visits has also grown progressively from 49% in 2002 to 98% 
in 2011. The percentage of HIV-infected babies has also dropped markedly as a result of 
PMTCT intervention. It recorded an admirably low 2.3% HIV-infection rate in babies in 
2008. The average percentage of HIV-infected babies between 2008 and 2011 was 3.68%. 
(MOH PMTCT Program National database statistics, 2011). PMTCT has been documented 
as having registered the greatest prevention success among all other HIV prevention 
strategies (Celentano D., Beyrer C., (Ed) 2008).   
 
4.2 PMTCT treatment regimen used in Botswana and its current impact 
 
PMTCT therapy in Botswana was initially based on a single drug zidovudine given as a short 
course treatment on a United Nations Agency supported PMTCT pilot (Celentano et al (Ed) 
2008, page 307). It has however evolved and developed to the more effective combination 
therapy utilized at present.  
 
The current Botswana annual National Summary of the PMTCT program (January 2011 to 
December 2011) report show that in 2011, a total of 50,812 recorded new attendees accessed 
ante-natal clinic services in Botswana. Of this number, 36,027 women representing 89% were 
tested for HIV in ANC. A total of 33% of the women who delivered were HIV positive. 
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The total deliveries recorded in 2011 was 47,443, of which 12,738 women who delivered 
were HIV positive and were on treatment or on prophylactic therapy (PMTCT). Of these, 
53% were on Zidovudine, and 40% were on HAART during ANC. This gives a PMTCT 
program uptake of 93% in 2011. 
 
Of the children born to HIV positive mothers, 93% (13,101) were started on prophylactic 
antiretroviral treatment using Zidovudine/Nevirapine. A total of 92% (12,979) of the infants 
were started on formula feeding. The records show that 87% of the infants (12,263) were 
tested for HIV and of these, 247 were HIV positive. This gives an infant HIV infection rate of 
4% in 2011 as a result of PMTCT intervention. This value of 4% infant infection rate, though 
quite an impressive achievement, is more than the <2% WHO ultimate hallmark of an 
excellent PMTCT program. This allows room for improvement of the program to achieve the 
<2% infant infection rate expectation.  
 
HIV testing is routine and recommended in Botswana, but it is not mandatory. The male 
partners of the pregnant mothers attending ANC are encouraged to test for HIV infection. In 
2011, 5,183 male partners were tested representing a 14% male testing rate. 
Addendum 6 shows the PMTCT treatment algorithm presently used in Botswana. 
 
4.3 Adherence 
 
4.3.1 Antiretroviral Treatment Adherence 
 
Osterberg and Blaschke (2005) defined adherence to medication generally as the extent to 
which patients take medications as prescribed by their healthcare providers. The rates of 
adherence for individual patients are usually reported as the prescribed doses of the 
medication actually taken by the patient over a specified period. For successful treatment, an 
adherence level of over 95% is usually expected for optimum viral suppression in an HIV 
infected individual on antiretroviral therapy (Mannheimer, Friedland, Matts, Child, & 
Chesney, 2002). It therefore follows that the importance of adherence to antiretroviral 
medication cannot be over-emphasized. 
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There are many barriers to adherence and many reasons why patients do not adhere to 
medication. The factors affecting the adherence to antiretroviral therapy has been outlined 
and ranges from patient variables such as social and demographic factors, psychosocial 
factors, socio-cultural factors to factors relating to the type of treatment regimen involved, 
disease characteristics, clinic setting, and relationship between patient and healthcare 
provider (Edward, Machtinger, & Bangsberg, 2005; Kgatlwane, Madaki, Ogenyi, Moyo, 
Ekezie, & Moroka, 2006).  
 
4.3.2 Adherence and barriers to PMTCT 
 
Not much research has been done on antiretroviral PMTCT adherence in Botswana. As the 
number of pregnant mothers on PMTCT continues to increase, the PMTCT program can 
become more successful with more attention given to patient adherence to the preventive 
therapy. 
 
Studies elsewhere has shown a non-adherence rate of 21.7% to antiretroviral preventive 
therapy in HIV positive pregnant women, with forgetfulness being the most cited reason for 
non-adherence (Igwegbe, Ugboaja, & Nwajiaku, 2010). The factors that inhibit general 
antiretroviral treatment adherence also relate to adherence to PMTCT therapy alongside other 
peculiar pregnancy related factors such as morning sickness, GIT upsets, fear of potential 
effect of drug on foetus (Kartikeyan et al., 2007), and mood changes amongst others.  
Kebaabetswe P. M. (2007) identified stigma, fear of knowing one's own HIV status, fear of 
diagnosis, disclosure, infant feeding distribution stigma, lack of male partners’ support and 
negative attitudes of health workers, loss to follow up, inadequate care providers, lack of 
prenatal care, and weak health infrastructure as barriers to participation in the PMTCT 
program in Botswana. Some of these factors were studied closely in this research as barriers 
to adherence for those already on PMTCT therapy. The relative importance of the factors that 
may act as adherence barriers or predictors of low adherence in this population were also 
assessed. 
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4.3.3 Measurement of adherence 
 
The provision of free medicines do not guarantee patient adherence to the drugs provided, 
hence the need to develop adherence measurement and monitoring systems which should 
preferably be built into treatment protocols (Kartikeyan S., Bharmal R. N., Tiwari R. P., & 
Bisen P. S., 2007). Measuring adherence to medication involves the frank cooperation of the 
patient and the healthcare worker or researcher. This is because obtaining values that describe 
adherence do not necessarily translate to the patient actually taking the medication, except in 
cases of direct observed therapy, which is often not applicable in most settings where chronic 
medication is involved such as treatment of HIV and AIDS. 
 
There have been attempts however, to device workable adherence measurements and the 
most common methods are those outlined by Edward et al (2005). They include the use of 
computerized software systems such as the MEMS Caps which involves the use of a 
computer chip embedded on the medication cap which records the number of times the 
medication is opened to be accessed, use of the pill count system, use of biological markers, 
and analysis of pharmacy dispensing records. Other tools for measuring adherence include 
pill identification tests, issuing pill calendars, adherence partner, using recall questionnaires 
(Kartikeyan S. et al, 2007), and other self reporting systems such as the virtual analogue 
scale. 
 
The pill count and the visual analogue scale self reporting system was used to evaluate 
adherence in this research. The pill count basically compares a patient’s actual drug 
consumption with the expected consumption within a given period, or since the medication 
was last dispensed to the patient. The records and data obtained from the pill count can then 
be used to calculate the pill count adherence measures (Chalker, Andualem, Tadeg, Gitau, 
Ntaganira, Obua, & Waako, 2009). The visual analogue scale was described by Reips and 
Funke (2008) to be a psychometric response scale which can be used in questionnaires to 
measure subjective characteristics or attitudes that cannot be directly measured, by utilizing a 
continuous line between two end-points or scales, where respondents can specify their level 
of agreement to a statement by indicating a position along the continuous line or analogue 
scale. In this research, the participants indicated on a visual analogue scale their self assessed 
level of adherence to PMTCT therapy over the past one month. The pill count adherence 
measure and the virtual analogue scale have been used to measure adherence in other 
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antiretroviral therapy adherence studies (San Lio, Carbini, Germano, Guidotti, Mancinelli, 
Magid, Narciso, Palombi, Renzi, Zimba, & Marazzi 2008; Amico, Fisher, Cornman, Shuper, 
Redding, Konkle-Parker, Barta, & Fisher 2006; Ogenyi R. 2006). 
 
5. AIMS AND OBJECTIVES 
 
5.1 Aim of research 
 
The aim of the research was to determine the level of adherence to PMTCT among HIV 
infected pregnant women on PMTCT antiretroviral therapy, and to establish the factors that 
contribute to poor adherence and their relative importance, in order to provide intervention 
strategies to improve the adherence to therapy among this population in Area W Clinic, 
Francistown, Botswana. 
 
5.2 Objectives 
 
 To determine the extent of ART medication adherence of pregnant women on 
antiretroviral PMTCT therapy in Area W Clinic Francistown 
 To establish the level of knowledge of PMTCT patients regarding the importance of 
adherence to antiretroviral PMTCT treatment  
 To establish the factors influencing adherence and their relative importance as 
adherence predictors/barriers to PMTCT adherence in this population 
 To make recommendations for intervention strategies that will improve adherence to 
PMTCT therapy 
 
6. RESEARCH DESIGN AND METHODOLOGY 
 
The research was a prospective cross sectional study relying on purposeful sampling, semi-
structured questionnaires, and document observation. The study focused on HIV infected 
pregnant mothers on antiretroviral PMTCT therapy, and how they adhere to their treatment 
regimen.   
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The study design and methodology was approved by the Research Ethics Committee of 
Stellenbosch University, and the Health Research and Development Division of the Botswana 
Ministry of Health. Permission to carry out the research in Area W Clinic Francistown was 
granted by the Ministry of Health, and the Greater Francistown District Health Management 
Team. 
 
The PMTCT register and medication records of the pregnant patients on PMTCT 
antiretroviral therapy in the clinic were reviewed in the IDCC department of the clinic. The 
HIV positive pregnant patients attending ANC at the clinic were identified and approached to 
participate in the study. The inclusion criteria for participants were established HIV infection 
in pregnancy, and current enrolment on the PMTCT antiretroviral therapy program at the 
Area W Clinic for the prevention of transmission of the HIV virus to the unborn child. The 
exclusion criteria were HIV infected pregnant women who refuse PMTCT, or who do not 
qualify for PMTCT, and those who refuse, or withdrew their consent to participate in the 
study. A written and signed informed consent was obtained from all those who accepted to 
enrol in the research. 
 
A total of seventy pregnant women on highly active antiretroviral therapy (HAART) in the 
clinic, were originally sampled to participate in the study. Of these, sixty one enrolled and 
completed the study giving a response rate of 87%. The interview/survey was conducted in 
either English or Setswana in private, under strict confidentiality by way of a structured 
questionnaire in one of the patient-counselling offices of the clinic by the principal 
investigator and a locally trained data collector. The data collector was trained to assist with 
administration of the questionnaires. The training was done by way of role playing, thorough 
study and perusal of the research protocol, and on the processes and procedures to be 
followed during the interview.  
 
The questionnaire used obtained information on demographics, social/marital status, and 
alcohol intake. Participant's medication taking patterns were also analyzed by inquiring about 
missed doses within the last three days before the interview and missed doses during the 
weekend preceding the interview. Information on perceived predictors of adherence and their 
relative importance, and subject’s level of knowledge on the importance of adherence to ART 
were also obtained. Parts of the questionnaire were modified from the NIH/NIAID 
QOL/Adherence forms by the AIDS Outcomes Committee of the AIDS Clinical Trials Group 
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(2008). Adherence levels were investigated using a one month recall measure, utilizing 
dispensing records, pill count, and a self reporting measure via a visual analogue scale.  
 
7. MEASURING INSTRUMENTS AND DATA ANALYSIS 
 
The data was analyzed using percentages and other descriptive methods of analysis. The 
software used was the Microsoft Excel and the SPSS data analysis. 
 
Adherence obtained from the pill count calculations and the virtual analogue scale were 
compared and considered optimum if greater than or equal to 95%. Adherence values below 
95% were considered sub-optimal. The relative importance of the selected adherence 
predictors was analyzed as well.  
 
Addendum 1 shows the adherence questionnaire and virtual analogue scale. Addendum 2 
shows the pill count data collection form and the formula used to calculate the percentage 
adherence by pill count. 
 
8. ETHICAL CONSIDERATIONS 
 
Authorization to carry out the research was sought from the relevant quarters and each 
subject participated voluntarily. Signed informed consent was obtained from each participant 
and questionnaires were answered anonymously without any reference to names or 
personality. 
 
The incentive to the participant was the knowledge that the research outcome shall highlight 
the peculiar issues that concern PMTCT treatment adherence and barriers to PMTCT 
treatment adherence in pregnant mothers thereby enabling strategic interventions to be made. 
 
Pregnant mothers on antiretroviral preventive therapy may be a sensitive population as there 
are often emotional issues surrounding their HIV status and the outcome of the status of the 
unborn child. As a result, counselling was offered after the exercise for those who required it. 
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9. RESULTS 
 
The results are presented in line with the study objectives and demographic characteristics, 
and expressed in percentages and proportions utilizing tables and figures. 
  
9.1 Demographical Characteristics   
 
   
 
Figure 1. Age distribution of the respondents 
 
Figure 1 shows that majority of the respondents (75.4%) were between the ages of 26 to 42 
years while 24.6% were between the ages of 20 to 25 years old.  
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Figure 2. Months of Pregnancy of the respondents 
 
Figure 2 shows the variations in months of gestation of the pregnant women. It depicted that 
participants in this study ranged from three months gestation, to full gestation or due for 
delivery. The figure also depicted that the majority of the pregnant women that participated in 
this study (57.4%) were six or seven months pregnant (n=35), eight of them were eight 
months pregnant, while only one of them was three months pregnant.  
Table 1  
Cross tabulation of employment status with education level and marital status 
 
Employed Not employed Total 
Frequency Percent Frequency Percent Frequency Percent 
Education 
level 
Primary 0 0.0 3 8.1 3 5.1 
Secondary 18 81.8 30 81.1 48 81.4 
Tertiary 4 18.2 4 10.8 8 13.6 
Marital 
status 
Single 22 95.7 32 86.5 54 90.0 
Married 1 4.3 4 10.8 5 8.3 
Widowed 0 0.0 1 2.7 1 1.7 
 
Table 1 shows majority of the respondents 81.4% (n=48) have attained secondary school, of 
which 30 of them, representing 62.5%  of those who had secondary school education were 
unemployed at the time of the study.  Three of the respondents had attended primary school, 
all of whom were unemployed. The results also depicted that majority (90%) of the 
respondents (n=54) were single of which 32 of them (59.3%) were unemployed at the time of 
this study. 
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9.2 Adherence levels to PMTCT therapy 
 
The data presented in this section addresses the first objective of determining the extent of 
ART medication adherence in pregnant women on PMTCT therapy in Area W Clinic 
Francistown. The result includes the three day adherence recall, adherence measured by self 
report using virtual analogue assessment, and adherence as calculated by the pill count. 
Presentation is done using proportions and percentages comprising of participants who 
demonstrated optimal adherence defined as achievement of >95% adherence and non- 
adherence defined as <95% adherence by each method. The medication taken by participants 
and their medication taking behaviour are also presented. 
 
 
 
Figure 3. Medication adherence recall over the last three days (N=61) 
 
Figure 3 shows that also all the respondents were consistent in taken their drugs (n=60), only 
one of them missed taking her drug within the three days preceding the interview. 
 
Table 2  
Medication taken by participants 
 
Multiple Responses 
Percent of Cases N=61 
CBV 8 13.1 
NVP 10 16.4 
ATRIPLA 47 77.0 
TRUVADA 5 8.2 
ALUVIA 3 4.9 
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From table 2, the names of the drugs taken by the respondents were Combivir (CBV), 
Nevirapine (NVP), ATRIPLA, TRUVADA and ALUVIA. The majority of the pregnant 
women (77.0%) that participated in this study were taking ATRIPLA only. For those on 
multiple pill combinations, 16.4% were taking either NVP, 13.1% were taking either CBV, 
TRUVADA was taken by 8.2% of the respondents and 4.9% of the pregnant women were 
taking ALUVIA,  all as part of a combination therapy. It is important to note that these drugs 
were taken in a combination therapy, except for ATRIPLA which is a single dose triple 
combination therapy drug formulation. 
 
Figure 4. One month adherence recall by virtual analogue scale 
 
Figure 4 show 84% optimum adherence by virtual analogues from the pregnant women that 
participated in this study, and 16% of them had adherence level below 95% based on the 
virtual analogue assessment.  
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Figure 5. Breakdown of reported adherence levels by virtual analogue scale 
 
Figure 5 shows the breakdown in the level of participants’ adherence to their medications 
using the analogue scale. The results show that majority of the participants (83%) reported a 
100% adherence rate, 15% of them reported 90% adherence rates, while 2% of the 
participants reported 80% adherence rate.  
 
Table 3  
ART medication taking behaviour of pregnant women on PMTCT 
 zero One Two Total 
Dose (No. of pills taken at a time) : CBV 0 7 1 8 
Dose (No. of pills taken at a time) : NVP 0 8 2 10 
Dose (No. of pills taken at a time) : ATRIPLA 0 48 0 48 
Dose (No. of pills taken at a time) : TRUVADA 0 5 0 5 
Dose (No. of pills taken at a time) : ALUVIA 0 0 3 3 
Frequency (No. of times taken in a day): CBV 0 1 7 8 
Frequency (No. of times taken in a day): NVP 0 1 8 9 
Frequency (No. of times taken in a day): ATRIPLA 0 47 0 47 
Frequency (No. of times taken in a day): TRUVADA 0 4 1 5 
Frequency (No. of times taken in a day): ALUVIA 0 0 3 3 
How many doses missed: CBV 8 0 0 8 
How many doses missed: NVP 10 0 0 10 
How many doses missed: ATRIPLA 45 0 1 46 
How many doses missed: TRUVADA 7 0 0 7 
How many doses missed: ALUVIA 3 0 0 3 
 
Table 3 demonstrates the behaviours of the respondents toward taking their medications. 
Eight of the respondents were taking CBV, of which majority of them (n=7) were taking a 
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pill at a time while one of them was taking two of the CBV at a time.  The majority of them 
(n=7) were taking CBV twice a day, a pregnant woman was taking CBV once a day and none 
of them had missed taking CBV medication. The prescribed dosage for CBV was one tablet 
to be taken twice a day. 
 
 
Figure 6. Adherence by pill count 
 
Furthermore, table 3 above shows that of all the 48 pregnant women that were taking 
ATRIPLA, 47 of them were taking one pill on a daily bases as prescribed, and only one of 
them had missed her pills twice. ALUVIA pills were taken by three pregnant women, two 
pills twice daily, while of the ten that were taking NVP, eight of them were taking a pill twice 
daily as prescribed, and two of them were taking two pills at once daily.  Finally, the graph in 
figure 6 shows a high level of adherence (n=50) from the participants by pill count.  
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Figure 7. Breakdown of participant’s adherence levels by pill count 
 
Figure 7 shows that 54% of the participants had 100% adherence levels from the pill count, 
18% of them had adherence levels ranging 95.2-99.4%, 13% of them had adherence levels of 
less than 95% which is below the optimum adherence desired, and 15% of them had 
adherence levels above 100% using the same method. 
9.3 Level of knowledge of participants regarding the importance of adherence to 
PMTCT treatment  
The result in this section expresses the level of knowledge participants have regarding the 
importance of adherence to PMTCT antiretroviral treatment in Area W Clinic Francistown. 
 
 
 
Somewhat sure Very sure 
Extremely 
sure Total 
Able to take all or most of  Anti-HIV 
medications as directed 
0 23 38 61 
The anti-HIV medication prevent HIV 
transmission to baby if well taken 
0 28 33 61 
If anti-HIV medication  was not taken 
Exactly as directed, the HIV in one’s  body 
Will become resistant to this medication 
2 23 36 61 
Figure 8. Participants level of knowledge about PMTCT treatment 
Figure 8 shows that majority of participants (n=34) had not previously been on HAART. The 
reason why the majority of them (n=37) were on HAART was because of PMTCT. 
Participants were consistent in taking their ARV drugs as directed. They all believed that 
anti-HIV medication prevent HIV transmission to baby if well taken, and two of them were 
not sure if anti-HIV medication not taken exactly as directed will result in the HIV in one’s  
body to become resistant to ARV medication. 
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9.4 Factors influencing PMTCT adherence and their relative importance as adherence 
predictors/barriers 
 
This section answers the third objective which was to establish the factors contributing to 
poor adherence and their relative importance as adherence predictors/barriers to PMTCT 
adherence in this population. 
Table 4 
Reasons for missing medications 
 Often Sometimes Rarely Never Total 
Wanted to avoid side effects 0 1 3 57 61 
Lack support from partner or spouse 0 1 1 59 61 
Not fully understanding how and when to take the 
medications 
0 0 2 59 61 
Lost pills 0 0 1 60 61 
Did not like the attitude of the health workers 1 2 2 56 61 
Had a bad event happen that you felt was related 
to taking the pills 
0 1 1 58 60 
Forgot 0 0 1 60 61 
Ran out of pills 0 0 1 60 61 
Tired of taking too many pills 0 0 1 60 61 
Felt the drugs may harm your baby 0 1 1 59 61 
Other illness, nausea, or some pregnancy related 
health problems got in the way 
0 5 2 54 61 
Stigmatization (what others may say or discover 
about my disease) by people outside of one’s 
family 
0 1 0 60 61 
Fear of stigmatization/disclosure within the home 
(e.g. not wanting the husband or family to know) 
0 1 0 60 61 
 
Table 4 shows some reasons why HIV pregnant women on PMTCT medication would want 
to miss their medications. Although the results depicted that almost all of them believed that 
there is no reason enough to stop anyone from taking their medications, but few of them gave 
the following reasons for missing the medications.  
Four of them stated that it was to avoid the drug side effects, two of them said they did not 
fully understand how and when to take their medication, while seven of them missed because 
some pregnancy related health problems got in the way. Other reasons were the attitude of the 
health workers (n=2), lost pills (n=1), and pill fatigue (n=1).  
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Table 5  
Factors influencing adherence among pregnant women  
  B S.E. Wald Sig. Exp(B) 
Education level -1.308 1.089 1.442 .230 .270 
Month of pregnancy -.563 .330 2.902 .088 .570*** 
Marital status -.113 1.166 .009 .923 .893 
Age  -.010 1.012 .000 .992 .990 
On HAART because of 
PMTCT 
-.875 1.085 .651 .420 .417 
Previous been on HAART 1.017 1.132 .807 .369 2.765 
Constant 8.245 4.812 2.936 .087 3809.901*** 
  
Cox & Snell R Square .133 
  Nagelkerke R Square 
.219 
Probabilities are computed assuming asymptotic normality. Critical values 1% *, Critical values at 5%** and Critical values at 10%*** 
Table 5 shows a binary logistic regression model where adherence was captured as a dummy 
variable (i.e. 1= adhered, 0= non-adherence). The results show that the month of pregnancy 
as a factor has a significant negative effect on the level of adherence, and the other factors 
had insignificant effects. In other words, as the pregnant women drew towards delivery, they 
became less likely to adhere to their medications. The results also stipulated that the level of 
the participants’ adherence to their medications was not influenced by the other factors. This 
inference can be deduced from the comparisons between the Exp (B) of the constant 
(3809.901) and Exp (B) coefficients of the variables in the model 
 
10. Analysis and discussion of results 
 
10.1 Demographics 
 
A total of 61 pregnant women participated in this study and their ages ranged from 20 years 
to 42 years. The majority of the respondents was over 26 years old, single, and had at least 
secondary school education. The respondents within the ages of 26 to 42 years formed the 
bulk of the pregnant women, representing 75.4% of total respondents in this study. 
Participants within the 20 to 25 years old age bracket made up 24.6%. This age demographics 
observed in the study was consistent with HIV and AIDS prevalence among pregnant women 
in Botswana which was reported to be highest in the 30 to 39 year old age group (MOH 
2012).   
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All the participants were within three to nine months gestation and had been enrolled onto the 
PMTCT program at least more than one month previously. The majority were at six and 
seven month’s gestation. 
 
10.2 Level of knowledge of importance of adherence 
 
Most of the participants (n=37) were antiretroviral treatment naive when they were initiated 
on PMTCT therapy as a result of pregnancy. The remaining twenty four participants were 
already on HAART before pregnancy. Some (n=20) however reported that they have 
previously taken antiretroviral therapy. It was not quite clear if these were among the twenty 
four that reported being on HAART before they became pregnant or if some had on a 
different occasion been on antiretroviral treatment, and had the treatment discontinued before 
being re-initiated onto the present PMTCT therapy. 
 
The participants however, demonstrated a good knowledge of the importance of treatment 
adherence in PMTCT therapy. This shows that adherence counselling in Area W Clinic was 
impactful and the patients, generally speaking, understood the need to adhere to their 
medication. This is also consistent with the quality of adherence observed in this study. 
However, there is room for improvement as two participants reported they did not quite fully 
understand the concept of virological resistance that can develop from poor adherence to 
antiretroviral therapy. 
10.3 Adherence levels 
 
The drugs administered to the women were in a combination therapy in accordance with the 
Botswana PMTCT treatment guidelines. The guideline prescribes the use of highly active anti 
retroviral therapy (HAART) mostly comprising of three different drugs in the treatment for 
PMTCT in HIV infection and has recently adopted the triple antiretroviral therapy for 
prophylaxis (TAP) for PMTCT (Keapoletswe, 2012). The drug Atripla was the only once a 
day medication that was prescribed to be taken alone and not in combination with another 
antiretroviral pill. This is because Atripla is a triple drug HAART combination, formulated as 
a single dose. Majority of the patients in this study were using Atripla following the 
implementation of TAP in Botswana. Of the 48 women on Atripla, only one missed her dose 
on two occasions. Atripla being a once a day dosage formulation decreases the number of 
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pills patients need to take and the frequency as well. This could potentially improve 
adherence levels. More needs to be done to find out if adherence levels to single dose 
formulations are better than multiple dose formulations in both pregnant and non pregnant 
patients on antiretroviral therapy. 
 
The other medications were either a two drug formulation (for example CBV, TRV, ALV), or 
a single drug formulation (NVP), intended to be taken one with another to obtain a complete 
HAART therapy. The women on multiple dosage regimens with requirements to swallow 
more than one pill a day showed different patterns of adherence. Most of them took their 
drugs as prescribed and adhered very well. Few on the other hand, though they did take their 
medications, however took them inappropriately. An example was a pregnant woman who 
reported taking two CBV tablets once a day instead of one tablet twice a day as prescribed, 
and two women who were taking two NVP pills once a day instead of the prescribed one pill 
twice a day. Such dosage errors can be overcome by counselling. It is therefore important for 
medication counselling and re-counselling to be re-enforced at every opportunity to help 
weed out such miss-understandings in medication usage. All the women on Aluvia took their 
pills as prescribed.  
 
The three day adherence recall for participants in the study was good with 98% of the 
participants reporting to have achieved optimum adherence to their PMTCT medication 
within the last three days preceding the interview, and none missing their medication during 
the last weekend preceding the interview.  
The results of the virtual analogue scale one month adherence recall self reporting system 
utilized in this study yielded an adherence level of 84%, and a non-adherence level of 16%. A 
breakdown of the analysis show that 83% of the participants (n=51) reported a 100% 
adherence, taking all their medication exactly as prescribed.  
 
The levels recorded using the pill count measurement were optimum adherence levels of 82% 
to PMTCT therapy, with a non adherence rate of 16%, and a 2% (n=1) non-indication. A 
breakdown of the pill count adherence show that 54% (n=33) of the participants obtained 
100% adherence, taking all the pills they were expected to have taken, and exactly as 
prescribed within the period. A further 18% of the participants (n=11) also achieved optimum 
adherence, recording adherence levels between 95-99%. Thirteen percent of the participants 
(n=8) however, did not achieve optimum adherence as their adherence levels were below the 
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desired 95%. It is important to point out that for some reason, 15% of the participants (n=9) 
exceeded 100% adherence, with the pill count showing that more pills were taken than 
expected with respect to the prescribed quantities. The reasons for this was not clear but it 
could be as a result of the participants actually consuming more pills than required, in which 
case it will constitute an over dosage. This can be corrected by intensifying adherence 
monitoring and counselling. It may also be due to loss of pills, hence the return of fewer pills 
than expected at the pill count. 
 
A comparison of both adherence measurement methods show a significant similarity and 
consistency in the levels of adherence reported by the participants via the virtual analogue 
scale, and that obtained by the more objective pill count. They also correspond with the level 
of adherence reported in the three day recall measure. These show that the levels of 
adherence in the pregnant population in the clinic were quite high. This finding correlates 
generally with the reported success of the PMTCT program in Botswana.   
 
The adherence rates, when compared to PMTCT adherence studies elsewhere in Africa such 
as the study conducted by Igwebe et al (2010), which reported a non adherence rate of 21.7%, 
show that there may be a higher adherence to PMTCT therapy in Botswana. The higher 
adherence rates may be contributory to the recorded success of the PMTCT program in 
Botswana as compared to some other African countries. 
 
Comparing the adherence recorded in this study with other HAART adherence studies carried 
out in Botswana in non-pregnant subjects such as the Barriers to Antiretroviral adherence for 
patients living with HIV infection and AIDS in Botswana by Weiser et al, (2003) which 
reported an adherence rate of 54% by self report and 56% by provider assessment; and the 
Ogenyi (2006) adherence study investigating adherence to antiretroviral therapy among 
paediatric patients in Mahalapye District Hospital, Botswana, which reported an optimal 
adherence rate of 20.8% by pill count measure, and a 76.3% by self report via a virtual 
analogue scale; as well as the Factors that facilitate or constrain adherence to antiretroviral 
therapy among adults at four public health facilities in Botswana: a pre-intervention study by 
Kgatlwane et al (2006) which reported an optimal adherence rate of 75% by pill count, 60% 
by virtual analogue scale, and 96% by a two day pre-interview adherence recall, all show that 
pregnant women on PMTCT may have better adherence levels to antiretroviral treatment than 
other populations on HAART in Botswana. This may be because pregnant women on 
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PMTCT are highly motivated to adhere to their medication, being keen to prevent vertical 
transmission to their children. Also, pregnant women on PMTCT typically visit the clinic on 
a monthly basis for ante-natal services and collection of their antiretroviral medication. This 
gives the healthcare workers a good opportunity to carry out continuous adherence 
counselling to ensure good adherence to therapy. Area W Clinic utilizes this opportunity to 
carry out adherence monitoring to ensure medication adherence. 
 
Adherence studies elsewhere in Africa in non pregnant adult subjects by Irude et al, (2005) 
reported an optimal adherence level of 21% among ARV users interviewed which was also 
below what was observed in this study. It therefore follows that pregnant women in Botswana 
on PMTCT demonstrate higher adherence rates to antiretroviral treatment than patients who 
are on antiretroviral treatment primarily for their own health. The reasons for the higher 
adherence rates among pregnant women need to be evaluated further in future studies as this 
may inform strategies to improve adherence in non-pregnant patients on antiretroviral 
treatment. 
 
10.4 Factors influencing adherence to PMTCT therapy and their relative importance 
 
This study reports a non-adherence rate of 16%. The most cited reason for non-adherence 
among the participants who did not demonstrate optimum adherence to treatment was that a 
pregnancy related illness such as nausea prevented them from achieving optimal adherence. 
The second most cited reason was medication side effects. It therefore becomes important for 
healthcare workers to consider prompt management of pregnancy related illness in patients 
on PMTCT, as well as to promptly manage medication side effects as these may impact 
negatively on medication adherence, and consequently PMTCT treatment failure. Other 
reasons cited were inadequate medication counselling, negative attitude of health workers, 
lost pills, and pill fatigue. The study also showed that the month of pregnancy had an effect 
on PMTCT treatment adherence as participants tend to adhere less to therapy as they 
approached delivery. This may be due to pill fatigue or due to some pregnancy related illness. 
The most important factors influencing adherence to PMTCT therapy and in order of their 
relative importance deduced from this study therefore, are pregnancy related illnesses, 
medication side effects, and month of pregnancy of the patient on PMTCT. 
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Comparing the most cited reasons for non-adherence to PMTCT therapy with other barriers 
to HAART in non-pregnant subjects identified in another study carried out in Botswana by 
Weiser et al (2003) which listed cost, stigma, travel/migration and side effects as barriers to 
adherence in non-pregnant adult patients, show that only side effects correlates with the 
findings of this study as a barrier to optimal adherence in pregnant women. Antiretroviral 
drugs are presently given free of charge to citizens of Botswana hence cost of medication did 
not play any role in the observed levels of adherence in this study. Some of the factors listed 
as barriers to enrolment onto the PMTCT program in Botswana in the Barriers to 
participation in the prevention of mother-to-child HIV transmission program in Gaborone, 
Botswana: A qualitative approach study by Kebaabetswe (2007) such as lack of male partner 
support, stigma and disclosure researched in this study did not significantly affect the rate of 
adherence for participants already enrolled on the PMTCT program in this study. The other 
factors investigated in this study did not show any significant influence on optimal adherence 
in the participants. This is elaborated by the high levels of adherence observed in the study. 
  
11. LIMITATIONS OF THE STUDY 
 
The study reported a high adherence rate for the majority of participants including those who 
were treatment naïve before being placed on HAART as a result of pregnancy. The scope of 
the study was unable to follow up participants to determine if the adherence currently 
reported will translate to adherence to HAART when the participants are eventually enrolled 
onto life-long antiretroviral therapy. 
 
PMTCT therapy in Botswana continues for six weeks after delivery. The study however 
focused only subjects during pregnancy. It was therefore unable to evaluate if there were 
changes in adherence in the subjects after delivery and if there is any post partum influences 
on adherence. 
 
Similarly, PMTCT therapy in Botswana also consists of neonatal antiretroviral interventions 
for the infant as well as infant feeding interventions. Adherence to these was not evaluated in 
the study.  
 
Finally, limitations of adherence measurements were encountered during the study. 
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12. CONCLUSION AND RECOMMENDATIONS 
 
The study was designed to determine the adherence levels among pregnant women on 
PMTCT, to establish their level of knowledge of the importance of adherence to PMTCT 
medication, and to identify the factors that influence adherence as well as their relative 
importance on the population studied.  
 
The study reported a consistent and high adherence rate for participants both by the three day 
adherence recall, and the virtual analogue scale as well as the pill count adherence measure. 
Ninety eight percent of participants reported they did not miss any dose during the last three 
days. Eighty four percent demonstrated optimal adherences on the virtual analogue scale, and 
the pill count recorded 82% adherences.  
 
The major reasons for non-adherence were medication side effects, and some pregnancy 
related illness which interfered with adherence. The month of pregnancy also had an 
influence on adherence as participants tended to adhere less as they got closer to delivery. 
The other adherence barriers studied did not show any significant impact on the adherence 
levels and this is reflected in the adherence levels reported. 
 
The majority of the participants demonstrated adequate knowledge on the importance of 
PMTCT medication adherence, showing that good counselling had been done prior to 
treatment initiation. 
 
The recommendations drawn from this study to improve adherence in pregnant women 
undergoing PMTCT therapy are as follows- 
 
1. Pregnant women on PMTCT should be carefully monitored for pregnancy related 
illness as these have been shown to affect adherence to PMTCT therapy.  
2. There is need for caregivers to promptly treat medication side effects whenever they 
occur in order to ensure optimum adherence. 
3. The healthcare workers should routinely ask about medication side effects and 
pregnancy related illnesses at consultation. 
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4. It is also important to carry out continuous medication adherence counselling among 
pregnant women on PMTCT, to re-enforce adherence and correct any potential 
dosage errors.   
5. Special attention should be given to pregnant women on PMTCT when they approach 
delivery, or when they are at term, to ensure that they continue to adhere to their 
treatment regimen and overcome any feelings of pill fatigue. 
 
In conclusion, adherence levels to PMTCT therapy in Area W Clinic were high and the 
patients are generally well educated on the importance of adherence to PMTCT therapy.  
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Addendum 1: Interview form 
PMTCT ADHERENCE QUESTIONNAIRE 
To determine the level of adherence of pregnant mothers to PMTCT in Area W Clinic Francistown 
 
Participant research number                        Date         
                                 dd                mm            yy 
 
Please check one box for each question where there are check boxes. If you do not wish to answer 
a question, please draw a line through it. 
A. Socio-demographic data 
Age (years) ……………….                   On HAART because of PMTCT?  Yes          No 
Months of pregnancy ……………         Date of initiation of PMTCT therapy……………. 
Education level-                                        Previously been on HAART?    Yes         No 
    Primary      Secondary   Tetiary  If yes, Date of initiation of HAART 
……………….. 
Employment status-Yes        No 
If yes, profession or job title…………………… 
Marital status-Single         Married         Divorced          Widowed 
Do you drink alcohol?              If yes, what do you drink? Beers         Wines         Others       
…………. 
                                         Yes        No                                                               
How often do you drink in a week?........................ 
 
B. Adherence  
1. How sure are you that: 
Please check one box for each question. 
                                                                    Not at all    Some what     Very    Extremely 
      Sure              sure     sure             sure 
a. You will be able to take all or most of your    
Anti-HIV medications as directed? ...............     0                         1                   2                 3 
                                                          
b. The anti-HIV medication will prevent HIV  
transmission to your baby if well taken?....        0                         1                   2                 3 
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c. If you do not take your anti-HIV medication 
Exactly as directed, the HIV in your body            0                        1                   2                 3 
Will become resistant to this medication?.... 
 
2. During the last three days did you miss any dose of your medications?     YES           NO    
3. Did you miss to take the dose of any of the following medications?    
  
Name of medicine Dose (No. of pills taken 
at a time) 
Frequency (No. of 
times taken in a day) 
How many doses did 
you miss? 
    
    
    
    
   
4. Some people find that they forget to take their pills on the weekend days. Did you miss any of 
your ARV   medications last Saturday or Sunday?          YES           NO 
 
People may miss taking their medications for various reasons. Here is a list of possible reasons why 
you may have missed taking any medications within the past month. 
5. In the past month, how often have you missed taking your medications because you: 
 Please check one box for each question. 
 
Never 
3 
Rarely 
2 
Sometimes 
1 
Often 
0 
a. Wanted to avoid side effects? ............................  
                                             
   
b. Lack support from partner or spouse?..............  
 
   
c. Not fully understanding how and when to take the 
medications?........................ 
    
   
 
   
d. Lost pills?............................ 
 
    
e. Did not like the attitude of the health 
workers?......... 
 
 
   
f. Had a bad event happen that you felt was related 
to taking the pills? 
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g. Forgot?  
 
 
              
h. Ran out of pills?  
 
   
i. Tired of taking too many pills? 
 
    
j. Felt the drugs may harm your baby?  
 
   
k. Other illness, nausea, or some pregnancy related 
health problems got in the way? 
 
    
l. Stigmatization (what others may say or discover 
about my disease) by people outside of one’s 
family? 
 
    
m. Fear of stigmatization/disclosure within the home 
(e.g. not wanting the husband or family to know)? 
 
 
 
   
n. Other-?  
 
   
If other, specify ------------------------------------------------------------ 
 
Virtual Analogue scale 
Consider the line below as a scale from 0 to 10 and score yourself by marking the point on the line 
that you think represents your overall level of adherence to the ARV medications 
 
 
  
0          1          2          3          4          5          6          7          8          9          10 
 
 
 
Thank you very much for completing these questions. 
 
Parts of this questionnaire was modified from the NIAID AIDS CLINICAL TRIALS GROUP questionnaires 
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Addendum 2: 
 
 
 
 
 
Pharmacy pill count data collection form   
Assigned Subject Research Number:                                          
 
 
 
Name of ARV Drug 
 
 
Dosage 
 (for example i bd, 
etc) 
 
Quantity given 
previously(P0) 
(qty dispensed 
+ 
any remaining pills) 
from pharmacy records 
 
  QUANTITY                                 DATE 
 
Quantity returned 
presently(P1) 
 
(Pill count) 
 
 
 
    
  QUANTITY                   DATE 
1.    
 
2.    
3.    
    
 
 
%ADHERENCE=  
 
Total # of pills provided at previous visit (P0) - # pills remaining(P1) 
--------------------------------------------------------------------------------------------- X 100%   
       # pills instructed to take daily x # days since last visit 
 
(office of Clinical Research, Health Sciences, University of Pittsburg, USA. November 17, 2010) 
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Addendum 3: Approval letter from health facility 
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Addendum 4: Approval letter from the Botswana Ministry of Health. 
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Addendum 5: Approval from Research and Ethics Committee (REC) Stellenbosch 
University 
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Addendum 6: Botswana PMTCT prophylaxis/treatment algorithm 
 
 
2012 Botswana National HIV and AIDS Treatment Guidelines, page 179 
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Addendum 7: Self assessment 
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